Skip to main content
Clinical Trials/NCT01902667
NCT01902667
Completed
Not Applicable

Preoperative Imaging in Retroperitoneal Sarcoma

Institute of Cancer Research, United Kingdom1 site in 1 country32 target enrollmentStarted: July 2013Last updated:
ConditionsCancer

Overview

Phase
Not Applicable
Status
Completed
Sponsor
Institute of Cancer Research, United Kingdom
Enrollment
32
Locations
1
Primary Endpoint
Prediction, by MRI, of early response to radiotherapy prior to tumour shrinkage

Overview

Brief Summary

This is a prospective observational study in which patients with untreated retroperitoneal sarcoma will have Magnetic Resonance Imaging (MRI) prior to surgery. In addition, patients who will be undergoing pre-operative radiotherapy will have an additional MRI scan at two weeks post radiotherapy. For both groups, the magnetic resonance images will be correlated with tumour pathology.

The study hypothesis is that Magnetic Resonance Imaging will provide a more accurate assessment of tumour volume and local staging than CT and will identify areas of altered oxygenation, cellularity and perfusion which change in response to radiotherapy before tumour shrinkage occurs.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients with retroperitoneal sarcomas planned for surgical resection +/- preoperative radiotherapy.

Exclusion Criteria

  • MRI incompatible metal implants
  • claustrophobia

Outcomes

Primary Outcomes

Prediction, by MRI, of early response to radiotherapy prior to tumour shrinkage

Time Frame: 2-4 weeks

Changes in volume, maximum axial diameter, ADC, F, D, D\*, T2, R2\* and enhancing fraction from baseline to post radiotherapy will be presented. A paired T-test (or Wilcoxon Signed Rank Test) may be used to test the difference between baseline and post radiotherapy. Differences in these values will be presented for responders and non-responders, which will be tested by independent T-test. Response will be determined by tumour size, enhancing fraction and histopathological evidence of response.

Secondary Outcomes

  • To determine the reproducibility of multi-parametric MRI measurements within tumour regions of interest in patients with retroperitoneal sarcoma.(1-7 days)

Investigators

Sponsor
Institute of Cancer Research, United Kingdom
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Nandita deSouza

Professor of Translational Imaging

Institute of Cancer Research, United Kingdom

Study Sites (1)

Loading locations...

Similar Trials